Uterine Cancer Diagnostics Market Set to Reach Valuation of USD 19,386.15 Million by 2030, Size, Share, Demand, Future Growth, Challenges and Competitive Analysis
SYDNEY, Jan. 24, 2023 /PRNewswire/ -- Data Bridge Market Research has recently published a Report, titled, "Uterine Cancer Diagnostics Market" The report offers an extensive analysis of key growth strategies, drivers, opportunities, key segment, Porter's Five Forces analysis, and competitive landscape. To thrive in this rapidly transforming marketplace, today's businesses call for innovative and superlative solutions. Being an outstanding resource of market info, an excellent Uterine Cancer Diagnostics market research report provides recent as well as upcoming technical and financial details of the industry to 2030. Clients accomplish unparalleled insights and acquaintance of the best market opportunities into their respective markets from this market report. Market segmentation is also covered in detail by considering several aspects that is sure to help businesses out there. Global Uterine Cancer Diagnostics market report provides in-depth market data and forecast by analyzing key business trends and identifying potential growth avenues across the entire value chain.
Data Bridge Market Research analyzes that the Global uterine cancer diagnostics market is expected to reach the value of USD 19,386.15 million by 2030, at a CAGR of 10.7% during the forecast period. Diagnostic type accounts for the largest segment in the market due to the increase in the obesity rate among the women population and rising uterine cancer patients globally. This market report also covers pricing analysis, patent analysis and technological advancements in depth.
Download Sample Copy of Uterine Cancer Diagnostics Market @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-uterine-cancer-diagnostics-market
Market Overview:
Diagnosis of uterine cancer includes ultrasound, biopsy procedures and blood tests. Ultrasound tests use sound waves and produce images of the ovaries and uterus. Two types of ultrasound are included in diagnostic testing for uterine cancer: abdominal ultrasound and transvaginal ultrasound. An abdominal scan test involves scanning the full bladder with a small probe across the abdomen, while a transvaginal scan involves inserting a probe tube into the vagina to scan or create an image. Biopsy procedures include endometrial biopsy, hysteroscopy and dilation and curettage.
Uterine cancer is the most common cancer that occurs in the female reproductive system. It is a malignant tumor that starts in the uterus cells and can spread to other body parts. According to research by the American Cancer Society (ACS), uterine sarcoma accounts for 5% of all uterine cancers worldwide, while endometrial cancer is the most common form of uterine cancer.
Opportunities for Players:
- Increasing prevalence of uterine cancer
Uterine cancer is the most common type of gynecologic cancer. Over 90% of uterine cancers begin in the endometrium, the tissue lining the uterus. As the prevalence is increasing, the introduction of promising new treatments and therapeutic biologics and the rapid growth of hormone-resistant cancer drugs due to fewer side effects are also increasing. Awareness of the incidence of uterine cancer is growing among patients and healthcare providers, who are now becoming more active in learning about the diagnosis and treatments available for these diseases, which is expected to act as an opportunity for the market's growth.
Rates of new uterine cancer cases have risen 0.6% per year from 2010-2019 and death rates have risen an average of 1.7% per year for the same time frame. As the uterine cancer patient rate is increasing, the use of treatments and advanced technologies for cancer diagnosis will increase, which is an opportunity for market growth.
Some of the major players operating in the Uterine Cancer Diagnostics market are:
F-Hoffmann La Roche Ltd., Siemens Healthcare Private Limited, Narang Medical Limited, ESAOTE SPA, Olympus Corporation, Arquer Diagnostics Ltd, Guzip Biomarkers Corporation, General Electric, Canon Medical Systems ANZ Pty Limited., KARL STORZ, Medtronic, Stryker, Surtex Instruments Limited., Koninklijke Philips N.V., FUJIFILM Corporation, AED.MD, Jalal Surgical, Integra LifeSciences, B. Braun Melsungen AG and GRAIL
Recent Developments
- In November 2022, Koninklijke Philips N.V., announced the Global launch of a next-generation compact portable ultrasound solution at the Radiological Society of North America (RSNA) annual meeting to bring the diagnostic quality associated with premium cart-based ultrasound systems to more patients. It is portable and versatile with good image quality or performance. It is compatible with Philips ultrasound systems Affiniti and EPIQ transducer. This has helped the company to expand its product portfolio
- In April 2022, Medtronic and GE Healthcare announced a collaboration focused on the unique needs and demand for care at Ambulatory Surgery Centers (ASCs) and Office Based Labs (OBLs). Because of this collaboration, customers can access extensive product portfolios, financial solutions and exceptional service. GE Healthcare Interventional Imaging solutions are built to help our customers deliver care at a higher level for patients, which is very useful of cancer patients. This has helped the company to expand its business
Get Full PDF Research Report to Understand More @ https://www.databridgemarketresearch.com/checkout/buy/enterprise/global-uterine-cancer-diagnostics-market
The report provides insights on the following pointers:
Market Penetration: Comprehensive information on the product portfolios of the top players in the Uterine Cancer Diagnostics market
Product Development/Innovation: Detailed insights on upcoming technologies, R&D activities, and product launches in the market
Competitive Assessment: In-depth assessment of the market strategies, and geographic and business segments of the leading players in the market
Market Development: Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies
Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and Investments in the Uterine Cancer Diagnostics Market
Market Dynamics: Uterine Cancer Diagnostics Market
- Technological advancements in uterine cancer diagnostics
Uterine cancer is a ubiquitous gynaecological disease with many tests available for diagnosis, which include pelvic examination, endometrial biopsy, Dilation and Curettage (D&C), Transvaginal ultrasound, Computed Tomography (CT or CAT) scan, Magnetic Resonance Imaging (MRI) and biomarker testing of the tumor. Traditional means of detecting and monitoring cancers rely largely on imaging and, where possible, blood-based protein biomarkers, many of which are non-specific. Most cases of uterine cancer are diagnosed at late stages, as the presenting symptoms are often non-specific. The signs and symptoms of uterine cancer vary from person to person, making it difficult to provide accurate early diagnosis. This calls for personalized diagnostic plans, which involve multiple diagnostic tests.
Thus, technological advancements in uterine cancer diagnostics are expected to drive the market's growth.
- Rising demand for minimally invasive advanced screening techniques
Uterine cancer, especially endometrial cancer, is the fifth most common cancer in women in very high human development index regions based on age-standardized rates and its incidence has increased over the last few years. The standard strategy to diagnose endometrial cancer consists of office-based pelvic ultrasonography plus endometrial papilla sampling in cases of increased endometrial thickness. A hysteroscopy is recommended when the diagnosis is uncertain. Limitations include sample insufficiency in unsuccessful insertions (on occasions due to cervical stenosis or prolapse) and as well an abnormal sonographic appearance of the endometrium. Hence several limitations are associated with so-called standard methods of a uterine cancer diagnosis.
Thus, rising demand for minimally invasive advanced screening techniques are expected to drive the market's growth.
Consider Data Bridge Market Research for this Report which would Help Impact Your Revenues Positively
- This study offers the latest product news, trends, and updates from the industry's leading players who have leveraged their market position.
- It also offers strategic plans and standards to arrive at informed business decisions adopted by the main players, thereby advocating your go to market strategies.
- In addition, it offers insights into the dynamics of customer behaviour that can help the organization better curate market strategies
- Usage of exclusive tailor-made tools along with primary research, secondary research and our in-house data model helps us in extracting the exact market numbers
- Mapping the customer in 3P grid comprising of Purpose, Planning and Positioning, thereby delivering a solution by keeping the prospecting client at the sweet spot
- The market research report includes all of the market's valuable elements, such as sales growth, product pricing & analysis, growth opportunities, and recommendations for addressing market challenges
- The report covers all the primary mergers & acquisitions, alliances, and collaborations that have generated additional opportunities for market players or in some cases, challenges
To Gain More Insights about this Research, Visit @ https://www.databridgemarketresearch.com/reports/global-uterine-cancer-diagnostics-market
Key Industry Segmentation: Uterine Cancer Diagnostics Market
BY DIAGNOSTIC TYPE
- Instrument Based
- Procedure Based
BY TYPE
- Endometrial Cancer
- Uterine Sarcoma
BY AGE GROUP
- <30 years
- 31-40 years
- 41-50 years
- 51-60 years
- >60 years
BY END USER
- Hospitals
- Diagnostic Centers
- Cancer Research Centers
- Ambulatory Surgical Centers
- Specialized Clinics
- Others
BY DISTRIBUTION CHANNEL
- Direct Tenders
- Third Party Distributors
Regional Analysis/Insights: Uterine Cancer Diagnostics Market
The countries covered in this Uterine Cancer Diagnostics market report U.S., Canada, Mexico, Germany, France, U.K., Italy, Russia, Spain, Netherlands, Switzerland, Norway, Poland, Sweden, Belgium, Turkey, Denmark, Finland and the rest of Europe, China, Japan, India, Australia, New Zealand, South Korea, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Taiwan and the rest of Asia-Pacific, South Africa, Saudi Arabia, Bahrain, U.A.E, Kuwait, Oman, Qatar, Egypt, Israel and the rest of Middle East And Africa, Brazil, Argentina and the rest of South America.
North America is expected to dominate the market due to the presence of key market players in the largest consumer market with high GDP. U.S. is expected to grow due to its latest advanced cancer diagnostic technology and inventions in uterine cancer diagnostics.
Table of Contents:
- Introduction
- Market Segmentation
- Executive Summary
- Premium Insights
- Global Uterine Cancer Diagnostics Market: Regulations
- Market Overview
- Global Uterine Cancer Diagnostics Market, By Type
- Global Uterine Cancer Diagnostics Market, By Age Group
- Global Uterine Cancer Diagnostics Market, By End User
- Global Uterine Cancer Diagnostics Market, By Distribution Channel
- Global Uterine Cancer Diagnostics Market, By Region
- Global Uterine Cancer Diagnostics Market: Company Landscape
- SWOT Analyses
- Company Profile
- Questionnaires
- Related Reports
To Check the Complete Table of contents, click here @ https://www.databridgemarketresearch.com/toc/?dbmr=global-uterine-cancer-diagnostics-market
Explore More Reports:
Europe Uterine Cancer Diagnostics Market, By Diagnostic Type (Instrument Based And Procedure Based), Type (Endometrial Cancer And Uterine Sarcoma), Age Group (<30, 31-40, 41-50, 51-60 And >60), End User (Hospitals, Diagnostic Centers, Cancer Research Center, Ambulatory Surgical Centers, Specialized Clinics And Others), Distribution Channel (Direct Tender, Third Party Distributors and Others) https://www.databridgemarketresearch.com/reports/europe-uterine-cancer-diagnostics-market
Asia-Pacific Uterine Cancer Diagnostics Market, By Diagnostic Type (Instrument Based And Procedure Based), Type (Endometrial Cancer And Uterine Sarcoma), Age Group (<30, 31-40, 41-50, 51-60 And >60), End User (Hospitals, Diagnostic Centers, Cancer Research Center, Ambulatory Surgical Centers, Specialized Clinics And Others), Distribution Channel (Direct Tender, Third Party Distributors and Others) https://www.databridgemarketresearch.com/reports/asia-pacific-uterine-cancer-diagnostics-market
Middle East and Africa Uterine Cancer Diagnostics Market, By Diagnostic Type (Instrument Based And Procedure Based), Type (Endometrial Cancer And Uterine Sarcoma), Age Group (<30, 31-40, 41-50, 51-60 And >60), End User (Hospitals, Diagnostic Centers, Cancer Research Center, Ambulatory Surgical Centers, Specialized Clinics And Others), Distribution Channel (Direct Tender, Third Party Distributors and Others) https://www.databridgemarketresearch.com/reports/middle-east-and-africa-uterine-cancer-diagnostics-market
North America Uterine Cancer Diagnostics Market, By Diagnostic Type (Instrument Based And Procedure Based), Type (Endometrial Cancer And Uterine Sarcoma), Age Group (<30, 31-40, 41-50, 51-60 And >60), End User (Hospitals, Diagnostic Centers, Cancer Research Center, Ambulatory Surgical Centers, Specialized Clinics And Others), Distribution Channel (Direct Tender, Third Party Distributors and Others) https://www.databridgemarketresearch.com/reports/north-america-uterine-cancer-diagnostics-market
North America Intrauterine Contraceptive Devices Market, By Type (Hormonal Intrauterine Device, Copper Intrauterine Device), End User (Hospitals, Gynecology Clinics, Community Health Care Centers, Other), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Clinics, Online Channel, Public Channel and NGOs, Others), Country (U.S., Canada, Mexico) – Industry Trends and Forecast to 2028North America Intrauterine Contraceptive Devices Market, By Type (Hormonal Intrauterine Device, Copper Intrauterine Device), End User (Hospitals, Gynecology Clinics, Community Health Care Centers, Other), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Clinics, Online Channel, Public Channel and NGOs, Others), Country (U.S., Canada, Mexico) https://www.databridgemarketresearch.com/reports/north-america-intrauterine-contraceptive-devices-market
Europe Intrauterine Contraceptive Devices Market, By Type of Product (Hormonal, IUCD and Copper IUCD), End Use (Hospitals, Gynecology Clinics, Community Healthcare and Others), Country (Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia and Rest of Europe) https://www.databridgemarketresearch.com/reports/europe-intrauterine-contraceptive-devices-market
Asia-Pacific Intrauterine Contraceptive Devices Market, By Type of Product (Hormonal, IUCD and Copper IUCD), End Use (Hospitals, Gynaecology Clinics, Community Healthcare and Others), Country (Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific) https://www.databridgemarketresearch.com/reports/asia-pacific-intrauterine-contraceptive-devices-market
About Data Bridge Market Research:
An absolute way to forecast what future holds is to comprehend the trend today!
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.
Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.
Contact Us:-
Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
Email:- corporatesales@databridgemarketresearch.com
Logo: https://mma.prnewswire.com/media/1011053/Data_Bridge_Market_Research_Logo.jpg
Share this article